Genkyotex wants to become a liver disease player, and it won’t let a detail like a trial failure put a brake on its ambitions. The company’s GKT831 has flunked a mid-stage study in its lead indication, primary biliary cholangitis, but Genkyotex claims to have seen enough to push on into phase III.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,